Page 42 - 80_01

SREBP-­-1c,
ChREBP
y
LXR…

47. Adiels,
M.,
Westerbacka,
J.,
Soro-­-Paavonen,
A.
y
col.
2007.
Acute
suppression
of
VLDL1

secretion
rate
by
insulin
is
associated
with
hepatic
fat
content
and
insulin
resistance.

Diabetologia
50,
2356-­-2365.

48. Choi,
S.H.,
Ginsberg,
H.N.,
2011.
Increased
very
low
density
lipoprotein
(VLDL)
secretion,

hepatic
steatosis,
and
insulin
resistance.
Trends
Endocrinol
Metab
22,
353-­-363.

49. Day,
C.P.,
James,
O.F.,
1998.
Steatohepatitis:
a
tale
of
two
"hits"?
Gastroenterology
114,

842-­-845.

50.
Trauner,
M.,
Arrese,
M.,
Wagner,
M.,
2010.
Fatty
liver
and
lipotoxicity.
Biochim

Biophys
Acta
1801,
299-­-310.

51. Pérez-­-Carreras,
M.,
Del
Hoyo,
P.,
Martín,
M.A.
y
col.
2003.
Defective
hepatic
mitochondrial

respiratory
chain
in
patients
with
nonalcoholic
steatohepatitis.
Hepatology
38,
999-­-1007.

52. Garcia-­-Ruiz,
C.,
Fernandez-­-Checa,
J.C.,
2006.
Mitochondrial
glutathione:
hepatocellular

survival-­-death
switch.
J
Gastroenterol
Hepatol
21
Suppl
3,
S3-­-6.

53. Maher,
J.M.,
2006.
Mechanisms
of
liver
injury
due
to
fat",
AASLD
Postgrad.
Course
Syllabus,

p.89-­-96.

54. Pessayre,
D.,
Fromenty,
B.,
2005.
NASH:
a
mitochondrial
disease.
J
Hepatol
42,
928-­-940.

55. Grieco,
A.,
Forgione,
A.,
Miele,
L.
y
col.
2005.
Fatty
liver
and
drugs.
Eur
Rev
Med
Pharmacol

Sci
9,
261-­-263.

56. Wieckowska,
A.,
Zein,
N.N.,
Yerian,
L.M.
y
col.
2006.
In
vivo
assessment
of
liver
cell

apoptosis
as
a
novel
biomarker
of
disease
severity
in
nonalcoholic
fatty
liver
disease.

Hepatology
44,
27-­-33.

57. Carter-­-Kent,
C.,
Zein,
N.N.,
Feldstein,
A.E.,
2008.
Cytokines
in
the
pathogenesis
of
fatty
liver

and
disease
progression
to
steatohepatitis:
implications
for
treatment.
Am
J
Gastroenterol

103,
1036-­-1042.

58. Feldstein,
A.E.,
2010.
Novel
insights
into
the
pathophysiology
of
nonalcoholic
fatty
liver

disease.
Semin
Liver
Dis
30,
391-­-401.

59. Stienstra,
R.,
Saudale,
F.,
Duval,
C.
y
col.
2010.
Kupffer
cells
promote
hepatic
steatosis
via

interleukin-­-1beta-­-dependent
suppression
of
peroxisome
proliferator-­-activated
receptor

alpha
activity.
Hepatology
51,
511-­-522.

60. Leonarduzzi,
G.,
Scavazza,
A.,
Biasi,
F.
y
col.
1997.
The
lipid
peroxidation
end
product
4-­-

hydroxy-­-2,3-­-nonenal
up-­-regulates
transforming
growth
factor
beta1
expression
in
the

macrophage
lineage:
a
link
between
oxidative
injury
and
fibrosclerosis.
FASEB
J
11,
851-­-

857.

61. Kaplowitz,
N.,
Than,
T.A.,
Shinohara,
M.,
Ji,
C.,
2007.
Endoplasmic
reticulum
stress
and
liver

injury.
Semin
Liver
Dis
27,
367-­-377.

62. Kammoun,
H.L.,
Hainault,
I.,
Ferré,
P.,
Foufelle,
F.,
2009.
Nutritional
related
liver
disease:

targeting
the
endoplasmic
reticulum
stress.
Curr
Opin
Clin
Nutr
Metab
Care
12,
575-­-582.

63. Ron,
D.,
Walter,
P.,
2007.
Signal
integration
in
the
endoplasmic
reticulum
unfolded
protein

response.
Nat
Rev
Mol
Cell
Biol
8,
519-­-529.

64. Gentile,
C.L.,
Frye,
M.,
Pagliassotti,
M.J.,
2011.
Endoplasmic
reticulum
stress
and
the

unfolded
protein
response
in
nonalcoholic
fatty
liver
disease.
Antioxid
Redox
Signal
15,

505-­-521.

65. Wang,
D.,
Wei,
Y.,
Pagliassotti,
M.J.,
2006.
Saturated
fatty
acids
promote
endoplasmic

reticulum
stress
and
liver
injury
in
rats
with
hepatic
steatosis.
Endocrinology
147,
943-­-

951.

66. Schenk,
S.,
Saberi,
M.,
Olefsky,
J.M.,
2008.
Insulin
sensitivity:
modulation
by
nutrients
and

inflammation.
J
Clin
Invest
118,
2992-­-3002.

67. Yamauchi,
T.,
Kamon,
J.,
Ito,
Y.
y
col.
2003.
Cloning
of
adiponectin
receptors
that
mediate

antidiabetic
metabolic
effects.
Nature
423,
762-­-769.

68. Yamauchi,
T.,
Kamon,
J.,
Minokoshi,
Y.
y
col.
2002.
Adiponectin
stimulates
glucose

utilization
and
fatty-­-acid
oxidation
by
activating
AMP-­-activated
protein
kinase.
Nat
Med
8,

1288-­-1295.

69. Wu,
X.,
Mahadev,
K.,
Fuchsel,
L.
y
col.
2007.
Adiponectin
suppresses
IkappaB
kinase

activation
induced
by
tumor
necrosis
factor-­-alpha
or
high
glucose
in
endothelial
cells:
role

of
cAMP
and
AMP
kinase
signaling.
Am
J
Physiol
Endocrinol
Metab
293,
E1836-­-1844.

70. Xu,
A.,
Wang,
Y.,
Keshaw,
H.
y
col.
2003.
The
fat-­-derived
hormone
adiponectin
alleviates

alcoholic
and
nonalcoholic
fatty
liver
diseases
in
mice.
J
Clin
Invest
112,
91-­-100.

41